{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:35Z","timestamp":1786986935447,"version":"build-2736575974"},"reference-count":149,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["BOE-A-2015-9456"],"award-info":[{"award-number":["BOE-A-2015-9456"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00598"],"award-info":[{"award-number":["PI16\/00598"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["SAF2016-75197-R"],"award-info":[{"award-number":["SAF2016-75197-R"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG\/GRK 2015\/1"],"award-info":[{"award-number":["DFG\/GRK 2015\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clinre.2017.12.006","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T09:41:54Z","timestamp":1520847714000},"page":"182-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Molecular bases of the poor response of liver cancer to chemotherapy"],"prefix":"10.1016","volume":"42","author":[{"given":"Jose J.G.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitane","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta R.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Osorio-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Santos-Llamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib0750","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/092986710790514462","article-title":"Molecular bases of liver cancer refractoriness to pharmacological treatment","volume":"17","author":"Marin","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinre.2017.12.006_bib0755","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20517\/2394-5079.2016.22","article-title":"Further understanding of mechanisms involved in liver cancer chemoresistance","volume":"3","author":"Briz","year":"2017","journal-title":"Hepatoma Res"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0760","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0765","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/156652410791608261","article-title":"Strategies for overcoming chemotherapy resistance in enterohepatic tumours","volume":"10","author":"Marin","year":"2010","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.clinre.2017.12.006_bib0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2017.06.005","article-title":"Chemoresistance and chemosensitization in cholangiocarcinoma","author":"Marin","year":"2018","journal-title":"Biochim Biophys Acta"},{"issue":"2\u20133","key":"10.1016\/j.clinre.2017.12.006_bib0775","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mam.2012.12.009","article-title":"The ABCs of membrane transporters in health and disease (SLC series): introduction","volume":"34","author":"Hediger","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib0780","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2005.07.032","article-title":"Membrane transporters and channels in chemoresistance and sensitivity of tumor cells","volume":"239","author":"Huang","year":"2006","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0785","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib0790","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1535-7163.MCT-13-0541","article-title":"OATP1A\/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice","volume":"13","author":"Iusuf","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib0795","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.28970","article-title":"Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel","volume":"136","author":"Iusuf","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinre.2017.12.006_bib0800","doi-asserted-by":"crossref","first-page":"863539","DOI":"10.1155\/2013\/863539","article-title":"Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy","volume":"2013","author":"Buxhofer-Ausch","year":"2013","journal-title":"J Drug Deliv"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib0805","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0810","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","article-title":"The SLC22 drug transporter family","volume":"447","author":"Koepsell","year":"2004","journal-title":"Pflugers Arch"},{"issue":"9","key":"10.1016\/j.clinre.2017.12.006_bib0815","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.18632\/oncotarget.15029","article-title":"The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma","volume":"8","author":"Geier","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0820","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/hep.26425","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib","volume":"58","author":"Herraez","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib0825","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinre.2017.12.006_bib0830","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2407-12-109","article-title":"Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance","volume":"12","author":"Heise","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinre.2017.12.006_bib0835","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.2741\/3527","article-title":"Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs","volume":"14","author":"Marin","year":"2009","journal-title":"Front Biosci (Landmark Ed)."},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0840","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/bjc.1991.328","article-title":"Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein","volume":"64","author":"Hunter","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinre.2017.12.006_bib0845","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0850","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1309\/AC1M-4TY4-U0TN-EN7T","article-title":"Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response","volume":"113","author":"Ng","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib0855","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jso.1129","article-title":"Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection","volume":"78","author":"Kato","year":"2001","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.clinre.2017.12.006_bib0860","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1478-3231.2008.01889.x","article-title":"Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin","volume":"28","author":"Vander Borght","year":"2008","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0865","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.20375","article-title":"Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling","volume":"40","author":"Lee","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib0870","first-page":"965","article-title":"Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma","volume":"23","author":"Korita","year":"2010","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib0875","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.1498","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma","volume":"94","author":"Nies","year":"2001","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0880","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.18632\/oncotarget.6889","article-title":"MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma","volume":"7","author":"Tomonari","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0885","first-page":"1465","article-title":"The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins","volume":"31","author":"Wakamatsu","year":"2007","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib0890","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/030089161009600115","article-title":"Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies","volume":"96","author":"Sun","year":"2010","journal-title":"Tumori"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0895","first-page":"2983","article-title":"ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients","volume":"36","author":"Chen","year":"2016","journal-title":"Anticancer Res"},{"issue":"2C","key":"10.1016\/j.clinre.2017.12.006_bib0900","first-page":"1045","article-title":"Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma","volume":"24","author":"Sugeno","year":"2004","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib0905","first-page":"347","article-title":"Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer","volume":"12","author":"Hotta","year":"2004","journal-title":"Oncol Rep"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib0910","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/labinvest.2017.51","article-title":"Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma","volume":"97","author":"Zhang","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.clinre.2017.12.006_bib0915","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OTT.S46498","article-title":"Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment","volume":"6","author":"Zhao","year":"2013","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib0920","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(19930101)71:1<36::AID-CNCR2820710107>3.0.CO;2-J","article-title":"The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma","volume":"71","author":"Murray","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib0925","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-7843.2007.00199.x","article-title":"Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines","volume":"102","author":"Takahata","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0930","doi-asserted-by":"crossref","first-page":"e96664","DOI":"10.1371\/journal.pone.0096664","article-title":"Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib0935","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.4081\/ejh.2016.2614","article-title":"Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma","volume":"60","author":"Fanni","year":"2016","journal-title":"Eur J Histochem"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib0940","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/gutjnl-2016-312734","article-title":"TSC1\/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication","volume":"66","author":"Ho","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0945","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tranon.2016.08.009","article-title":"Loss of tuberous sclerosis complex 2 (TSC2) as a predictive biomarker of response to mTOR inhibitor treatment in patients with hepatocellular carcinoma","volume":"9","author":"Cho","year":"2016","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0950","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/CAD.0b013e3283614fef","article-title":"Genetic polymorphisms of enzymes related to oral tegafur\/uracil therapeutic efficacy in patients with hepatocellular carcinoma","volume":"24","author":"Fushiya","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0955","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.asjsur.2015.04.008","article-title":"Administration of adjuvant oral tegafur\/uracil chemotherapy post hepatocellular carcinoma resection: a randomized controlled trial","volume":"39","author":"Ishizuka","year":"2016","journal-title":"Asian J Surg"},{"issue":"31","key":"10.1016\/j.clinre.2017.12.006_bib0960","doi-asserted-by":"crossref","first-page":"12938","DOI":"10.1073\/pnas.0901451106","article-title":"Identification of genes conferring resistance to 5-fluorouracil","volume":"106","author":"Yoo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2017.12.006_bib0965","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1749-6632.1996.tb26381.x","article-title":"Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin","volume":"803","author":"Li","year":"1996","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib0970","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-03-0362","article-title":"Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan","volume":"10","author":"Boyer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib0975","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jso.24086","article-title":"Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options","volume":"113","author":"Ang","year":"2016","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0980","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ijc.25114","article-title":"Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents","volume":"127","author":"Goasguen","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinre.2017.12.006_bib0985","doi-asserted-by":"crossref","first-page":"381602","DOI":"10.1155\/2015\/381602","article-title":"TOP2A amplification and overexpression in hepatocellular carcinoma tissues","volume":"2015","author":"Panvichian","year":"2015","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib0990","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/labinvest.3700254","article-title":"Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells","volume":"85","author":"Pang","year":"2005","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib0995","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ijc.23968","article-title":"TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance","volume":"124","author":"Wong","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1000","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1005","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1006\/bbrc.2001.4268","article-title":"Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line","volume":"280","author":"Zhou","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7150\/jca.17640","article-title":"Protein regulator of cytokinesis PRC1 confers chemoresistance and predicts an unfavorable postoperative survival of hepatocellular carcinoma patients","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ijc.28772","article-title":"VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study","volume":"135","author":"Scartozzi","year":"2014","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1020","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/liv.12778","article-title":"Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment","volume":"35","author":"Negri","year":"2015","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1025","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1245\/s10434-010-1414-4","article-title":"Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma","volume":"18","author":"Ueda","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2005.02.020","article-title":"Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma","volume":"43","author":"Fautrel","year":"2005","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1035","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/sj.bjc.6604671","article-title":"Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin\/5-fluorouracil as first-line chemotherapy","volume":"99","author":"Pare","year":"2008","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1040","doi-asserted-by":"crossref","first-page":"e0123333","DOI":"10.1371\/journal.pone.0123333","article-title":"Reptin regulates DNA double strand breaks repair in human hepatocellular carcinoma","volume":"10","author":"Raymond","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-017-3345-y","article-title":"XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Cancer"},{"issue":"5015","key":"10.1016\/j.clinre.2017.12.006_bib1050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1471-4892(01)00059-5","article-title":"Cell death and cancer therapy","volume":"1","author":"Bunz","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1060","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.12659\/MSM.895592","article-title":"Expression of P53 and HSP70 in chronic hepatitis, liver cirrhosis, and early and advanced hepatocellular carcinoma tissues and their diagnostic value in hepatocellular carcinoma: an immunohistochemical study","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci Monit"},{"issue":"15","key":"10.1016\/j.clinre.2017.12.006_bib1065","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.onc.1210279","article-title":"TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer","volume":"26","author":"Hussain","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1070","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-14-0122","article-title":"Intratumor heterogeneity in hepatocellular carcinoma","volume":"21","author":"Friemel","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00280-004-0767-4","article-title":"Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line","volume":"53","author":"Chan","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1080","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1248\/bpb.30.1400","article-title":"Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells","volume":"30","author":"Takeba","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1085","first-page":"76","article-title":"Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402\/5-FU cells","volume":"25","author":"Li","year":"2004","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1478-3231.2007.01544.x","article-title":"Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma","volume":"27","author":"Gramantieri","year":"2007","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1095","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jhep.2008.12.032","article-title":"Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism","volume":"50","author":"Giovannini","year":"2009","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2017.12.006_bib1100","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.18632\/oncotarget.1221","article-title":"Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma","volume":"4","author":"Giovannini","year":"2013","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2010.04.093","article-title":"Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways","volume":"396","author":"Mundt","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbrc.2004.01.118","article-title":"Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells","volume":"315","author":"Chun","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1115","first-page":"25","article-title":"Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma","volume":"28","author":"Fleischer","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1120","doi-asserted-by":"crossref","first-page":"409272","DOI":"10.1155\/2014\/409272","article-title":"The role of hypoxia inducible factor-1 in hepatocellular carcinoma","volume":"2014","author":"Luo","year":"2014","journal-title":"Biomed Res Int"},{"issue":"26","key":"10.1016\/j.clinre.2017.12.006_bib1125","doi-asserted-by":"crossref","first-page":"22880","DOI":"10.18632\/oncotarget.4412","article-title":"Co-expression of CXCL8 and HIF-1alpha is associated with metastasis and poor prognosis in hepatocellular carcinoma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1130","first-page":"565","article-title":"Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells","volume":"24","author":"Zhu","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00109-010-0623-4","article-title":"Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma","volume":"88","author":"Daskalow","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.clinre.2017.12.006_bib1140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-7-27","article-title":"Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity","volume":"7","author":"Sermeus","year":"2008","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.clinre.2017.12.006_bib1145","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/MCB.00166-09","article-title":"Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains","volume":"29","author":"Bellot","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1150","doi-asserted-by":"crossref","DOI":"10.2174\/1568009617666170427104356","article-title":"Epithelial-to-mesenchymal transition: a mediator of sorafenib resistance in advanced hepatocellular carcinoma","author":"Mir","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yexmp.2010.10.003","article-title":"Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study","volume":"90","author":"Na","year":"2011","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1160","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/hep.26255","article-title":"alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma","volume":"57","author":"Huang","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1165","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2010.12.043","article-title":"Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations","volume":"55","author":"Chen","year":"2011","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1170","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1002\/ijc.29097","article-title":"A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells","volume":"136","author":"Fernando","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1175","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.27887","article-title":"MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4","volume":"62","author":"Zhou","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.26369","article-title":"MicroRNA-216a\/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer","volume":"58","author":"Xia","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2017.12.006_bib1185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.biopha.2017.01.013","article-title":"HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition","volume":"88","author":"Xu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinre.2017.12.006_bib1190","doi-asserted-by":"crossref","first-page":"e2201","DOI":"10.1038\/cddis.2015.324","article-title":"Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK\/PI3K\/AKT signaling","volume":"7","author":"Zhang","year":"2016","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.clinre.2017.12.006_bib1195","doi-asserted-by":"crossref","first-page":"e78675","DOI":"10.1371\/journal.pone.0078675","article-title":"The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance","volume":"8","author":"Chow","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.leu.2403271","article-title":"Nucleoside transporters in chronic lymphocytic leukaemia","volume":"18","author":"Pastor-Anglada","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1205","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ejca.2011.11.006","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma","volume":"48","author":"Borbath","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1210","first-page":"857","article-title":"Prevalence of CTR1 and ERCC1 polymorphisms and response of biliary tract cancer to gemcitabine-platinum chemotherapy","volume":"18","author":"Pongmaneratanakul","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1215","first-page":"296","article-title":"Clinical relationship between MDR1 gene and gallbladder cancer","volume":"3","author":"Wang","year":"2004","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.clinre.2017.12.006_bib1220","first-page":"125","article-title":"High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma","volume":"13 suppl.","author":"Srimunta","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"30","key":"10.1016\/j.clinre.2017.12.006_bib1225","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3748\/wjg.v18.i30.3955","article-title":"Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil","volume":"18","author":"Hahnvajanawong","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1230","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/jpet.103.052696","article-title":"Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester","volume":"306","author":"Nakajima","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.clinre.2017.12.006_bib1235","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.humpath.2009.01.026","article-title":"Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors)","volume":"40","author":"Schmitz","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1240","article-title":"Molecular bases of chemoresistance in cholangiocarcinoma","author":"Marin","year":"2015","journal-title":"Curr Drug Targets"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1245","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-011-1558-3","article-title":"Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients","volume":"68","author":"Hwang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bbrc.2010.11.130","article-title":"Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1\/2","volume":"405","author":"Yoon","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1255","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000151541","article-title":"Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines","volume":"54","author":"Namwat","year":"2008","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1260","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3892\/ijo.2015.3188","article-title":"Targeting the 133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells","volume":"47","author":"Nutthasirikul","year":"2015","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1265","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.28496","article-title":"FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling","volume":"63","author":"Guan","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.clinre.2017.12.006_bib1270","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.18632\/oncotarget.830","article-title":"Targeting tumor stroma: exploiting apoptotic priming","volume":"3","author":"Mertens","year":"2012","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1275","first-page":"957","article-title":"Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma","volume":"21","author":"Chuaysri","year":"2009","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.clinre.2017.12.006_bib1280","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2015.11.011","article-title":"Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche","volume":"64","author":"Govaere","year":"2016","journal-title":"J Hepatol"},{"issue":"28","key":"10.1016\/j.clinre.2017.12.006_bib1285","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.18632\/oncotarget.4482","article-title":"Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K\/AKT-dependent Mcl-1 activation","volume":"6","author":"Morton","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.clinre.2017.12.006_bib1290","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/jcm4121958","article-title":"Epithelial-to-mesenchymal transition and cancer invasiveness: what can we learn from cholangiocarcinoma?","volume":"4","author":"Brivio","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinre.2017.12.006_bib1295","doi-asserted-by":"crossref","first-page":"36138","DOI":"10.1038\/srep36138","article-title":"Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1300","first-page":"3591","article-title":"Nimotuzumab inhibits cholangiocarcinoma cell metastasis via suppression of the epithelial-mesenchymal transition process","volume":"37","author":"Padthaisong","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinre.2017.12.006_bib1305","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2741\/e393","article-title":"Activation of Wnt and Myc signaling in hepatoblastoma","volume":"4","author":"Cairo","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1315","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","article-title":"The genomic landscape of hepatoblastoma and their progenies with HCC-like features","volume":"61","author":"Eichenmuller","year":"2014","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2017.12.006_bib1320","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1872-034X.2008.00381.x","article-title":"Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro","volume":"38","author":"Vander Borght","year":"2008","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1325","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.10858","article-title":"The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model","volume":"95","author":"Warmann","year":"2002","journal-title":"Cancer"},{"issue":"Pt 1","key":"10.1016\/j.clinre.2017.12.006_bib1330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BST0330241","article-title":"ABC transporters in the balance: is there a role in multidrug resistance?","volume":"33","author":"Polgar","year":"2005","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"10.1016\/j.clinre.2017.12.006_bib1335","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1021\/mp300249s","article-title":"BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo","volume":"9","author":"Zhang","year":"2012","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1340","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biotechadv.2013.06.004","article-title":"Different strategies to overcome multidrug resistance in cancer","volume":"31","author":"Saraswathy","year":"2013","journal-title":"Biotechnol Adv"},{"issue":"23","key":"10.1016\/j.clinre.2017.12.006_bib1345","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4254\/wjh.v8.i23.985","article-title":"Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-kappaB gene transcription","volume":"8","author":"Wu","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1350","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12935-015-0269-y","article-title":"Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms","volume":"15","author":"Yu","year":"2015","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2011.01.025","article-title":"Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression","volume":"304","author":"Ye","year":"2011","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1360","article-title":"Hepatoblastoma etiopathogenesis","volume":"7","author":"Macias","year":"2016","journal-title":"J Carcinog Mutagene"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1365","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbagen.2016.04.007","article-title":"Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents","volume":"1860","author":"Jia","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20132","key":"10.1016\/j.clinre.2017.12.006_bib1370","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11010-015-2518-8","article-title":"Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity","volume":"409","author":"Scoparo","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clinre.2017.12.006_bib1375","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejphar.2014.03.043","article-title":"Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2\/ADM and MCF-7\/ADR cells","volume":"733","author":"Liu","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1380","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3892\/ijo.2015.2925","article-title":"Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2\/ADM cells","volume":"46","author":"Liu","year":"2015","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2017.12.006_bib1385","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3109\/13880209.2014.952836","article-title":"Effect of shikonin on multidrug resistance in HepG2: the role of SIRT1","volume":"53","author":"Jin","year":"2015","journal-title":"Pharm Biol"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1390","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3892\/mmr.2013.1742","article-title":"Icaritin reverses multidrug resistance of HepG2\/ADR human hepatoma cells via downregulation of MDR1 and Pglycoprotein expression","volume":"8","author":"Sun","year":"2013","journal-title":"Mol Med Rep"},{"issue":"8","key":"10.1016\/j.clinre.2017.12.006_bib1395","doi-asserted-by":"crossref","first-page":"e40720","DOI":"10.1371\/journal.pone.0040720","article-title":"Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-kappaB in R-HepG2 cell line","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.clinre.2017.12.006_bib1400","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.phymed.2013.04.014","article-title":"Steroidal saponin of Trillium tschonoskii. Reverses multidrug resistance of hepatocellular carcinoma","volume":"20","author":"Wang","year":"2013","journal-title":"Phytomedicine"},{"issue":"1\u20133","key":"10.1016\/j.clinre.2017.12.006_bib1405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2010.09.011","article-title":"C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line","volume":"649","author":"Nishanth","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.clinre.2017.12.006_bib1410","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/157340611796799087","article-title":"Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1","volume":"7","author":"Achari","year":"2011","journal-title":"Med Chem"},{"issue":"2","key":"10.1016\/j.clinre.2017.12.006_bib1415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2010.12.018","article-title":"Reversal effect of Dioscin on multidrug resistance in human hepatoma HepG2\/adriamycin cells","volume":"654","author":"Sun","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1420","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2017.03.045","article-title":"Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2\/P-gp dependent pathway","volume":"803","author":"Xu","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2015.03.003","article-title":"Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice","volume":"93","author":"Zhao","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.clinre.2017.12.006_bib1430","first-page":"11934","article-title":"Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402\/5-FU and HepG2\/ADM cell lines","volume":"8","author":"Qian","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"10.1016\/j.clinre.2017.12.006_bib1435","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/j.2042-7158.2012.01549.x","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II","volume":"64","author":"Huang","year":"2012","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1440","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3892\/or.2013.2817","article-title":"Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402\/5-FU cells","volume":"31","author":"Gu","year":"2014","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1445","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/fon.13.15","article-title":"Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide","volume":"9","author":"Liu","year":"2013","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.clinre.2017.12.006_bib1450","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.phymed.2011.04.001","article-title":"Reversal effect of 2\u2032,4\u2032-dihydroxy-6\u2032-methoxy-3\u2032,5\u2032-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402\/5-FU","volume":"18","author":"Huang","year":"2011","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.clinre.2017.12.006_bib1455","first-page":"111","article-title":"Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer","volume":"37","author":"Liang","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clinre.2017.12.006_bib1460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2017.03.011","article-title":"Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402\/5-FU cells","volume":"131","author":"Zhang","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"28","key":"10.1016\/j.clinre.2017.12.006_bib1465","doi-asserted-by":"crossref","first-page":"25149","DOI":"10.18632\/oncotarget.4438","article-title":"An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"10.1016\/j.clinre.2017.12.006_bib1470","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3727\/096504015X14424348426071","article-title":"Inhibition of NF-kappaB activity enhances sensitivity to anticancer drugs in cholangiocarcinoma cells","volume":"23","author":"Seubwai","year":"2016","journal-title":"Oncol Res"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1475","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3892\/or.2014.3151","article-title":"Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines","volume":"31","author":"Ling","year":"2014","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.clinre.2017.12.006_bib1480","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.3892\/mmr.2014.2614","article-title":"Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402\/5fluorouracil cells","volume":"10","author":"Ling","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clinre.2017.12.006_bib1485","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2867-14-68","article-title":"Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines","volume":"14","author":"Hahnvajanawong","year":"2014","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.clinre.2017.12.006_bib1490","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3748\/wjg.v21.i4.1148","article-title":"beta-escin reverses multidrug resistance through inhibition of the GSK3beta\/beta-catenin pathway in cholangiocarcinoma","volume":"21","author":"Huang","year":"2015","journal-title":"World J Gastroenterol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118300299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118300299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:48Z","timestamp":1761895608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740118300299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":149,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2210740118300299"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2017.12.006","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular bases of the poor response of liver cancer to chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}